Emeline Mandon

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Sara C. Meyer, Matthew D. Keller, Sophia Chiu et al. · Cancer Cell · 2015 · 151 citations

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp et al. · Cancer Cell · 2015 · 120 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Malignant Blood Disorder +6

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 104 citations · Full text

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf ^−/− mouse model

Emilie A. Chapeau, Agnieszka Gembarska, Éric Durand et al. · Proceedings of the National Academy of Sciences · 2017 · 61 citations · Full text

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression

Emilie A. Chapeau, Emeline Mandon, Jason Gill et al. · PLoS ONE · 2019 · 10 citations · Full text

Hematological Malignancy, Knockout Mouse, Transgene Expression +13